OmniScreen Characterization

Paige OmniScreen™ Characterization is an AI-driven biomarker pre-screening solution developed by Paige, now a Tempus company. Designed for pharmaceutical companies, research organizations, and clinical settings, it offers a next-generation alternative to traditional molecular testing that is faster, more cost-effective, and requires significantly less tissue. By bridging the gap between pathology and genomics, OmniScreen enables study participant selection, more efficient testing strategies, and streamlined decision-making across both clinical and research workflows.

OmniScreen leverages novel AI technology to simultaneously screen over 1,200 clinically relevant biomarkers across multiple cancer types using standard H&E-stained slides. This makes it possible to unlock the potential of archival biospecimens that are often underutilized due to limited specimen information, providing in-depth molecular characterization without consuming valuable tissue.

Comprehensive Biomarker Profiling

• Predicts 1,228 biomarkers across 15 common cancer types, including clinically significant targets such as BRAF, EGFR, KRAS, MET, and FGFR3
• Provides a tissue-sparing alternative to traditional molecular testing and sequencing methods
• Operates directly from standard H&E-stained slides, eliminating the need for additional tissue preparation

Enhanced Tissue Characterization

• Strengthens phenotype-genotype linkages, offering deeper insights into molecular tumor profiles
• Enriches dataset quality for pharmaceutical companies and research organizations seeking well-characterized biospecimens
• Helps differentiate tissue and enhance inventory information with deep molecular insights

Operational and Cost Efficiencies

• Delivers biomarker predictions in minutes, significantly reducing reliance on manual pathology review
• Reduces dependence on costly sequencing tests by enabling AI-driven pre-screening
• Enables large-scale tissue characterization, making even extensive biospecimen collections more accessible and valuable

Optimized Specimen Utilization

• Identifies high-value tissue samples for targeted oncology research, improving specimen demand and revenue potential
• Enhances the value of archival biospecimen collections by providing previously unavailable molecular information
• Supports more efficient testing strategies by enabling informed selection of specimens prior to downstream molecular testing

Paige OmniScreen™ Characterization is suited for organizations looking to maximize the value of their pathology data and tissue collections at scale. By integrating AI-driven pre-screening into research and clinical workflows, it streamlines molecular biomarker identification and supports more informed, efficient decision-making across oncology research and drug development programs.